← Back to All US Stocks

Pluri Inc. (PLUR) Stock Fundamental Analysis & AI Rating 2026

PLUR Nasdaq Biological Products, (No Diagnostic Substances) NV CIK: 0001158780
Recently Updated • Analysis: Apr 14, 2026 • SEC Data: 2025-12-31
STRONG SELL
95% Conf
Pending
Analysis scheduled

📊 PLUR Key Takeaways

Revenue: $514.0K
Net Margin: -2,411.1%
Free Cash Flow: $-11.2M
Current Ratio: 0.43x
Debt/Equity: N/A
EPS: $-1.36
AI Rating: STRONG SELL with 95% confidence
Pluri Inc. (PLUR) receives a STRONG SELL rating with 95% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $514.0K, net profit margin of -2,411.1%, Pluri Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete PLUR stock analysis for 2026.

Is Pluri Inc. (PLUR) a Good Investment?

Claude

Pluri Inc. faces acute financial distress with negative stockholders' equity of -$14.6M, severely impaired liquidity (0.43x current ratio), and critical cash burn of $10.6M annually against only $514K in revenue. With approximately 4-5 months of cash runway at current burn rates and flat revenue growth, the company requires immediate capital infusion or faces insolvency.

Why Buy Pluri Inc. Stock? PLUR Key Strengths

Claude
  • + Positive gross margin of 39.1% on limited product sales demonstrates product unit economics
  • + Maintains $4.7M in cash reserves providing minimal operating runway
  • + Relatively low long-term debt of $1.3M limits near-term debt service obligations

PLUR Stock Risks: Pluri Inc. Investment Risks

Claude
  • ! Negative stockholders' equity of -$14.6M represents technical balance sheet insolvency
  • ! Severe liquidity crisis with current ratio of 0.43x - unable to cover short-term obligations with current assets
  • ! Operating cash burn of $10.6M annually against $514K revenue creates critical runway of 4-5 months
  • ! Flat revenue growth of 0% YoY indicates business is not achieving commercial traction or scaling
  • ! Operating losses of -$12.9M are 25x larger than revenue, indicating unsustainable unit economics at scale
  • ! Zero insider buying in past 90 days suggests lack of management confidence in company viability

Key Metrics to Watch

Claude
  • * Cash balance and monthly burn rate - company at critical juncture requiring capital raise or restructuring
  • * Revenue growth trajectory - must demonstrate traction to justify ongoing operations
  • * Path to profitability and operating expense reduction - current cost structure untenable
  • * Stockholders' equity progression - must return to positive equity to restore solvency

Pluri Inc. (PLUR) Financial Metrics & Key Ratios

Revenue
$514.0K
Net Income
$-12.4M
EPS (Diluted)
$-1.36
Free Cash Flow
$-11.2M
Total Assets
$30.6M
Cash Position
$4.7M

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

PLUR Profit Margin, ROE & Profitability Analysis

Gross Margin 39.1%
Operating Margin -2,501.2%
Net Margin -2,411.1%
ROE N/A
ROA -40.5%
FCF Margin -2,178.2%

PLUR vs Healthcare Sector: How Pluri Inc. Compares

How Pluri Inc. compares to Healthcare sector averages

Net Margin
PLUR -2,411.1%
vs
Sector Avg 12.0%
PLUR Sector
ROE
PLUR 0.0%
vs
Sector Avg 15.0%
PLUR Sector
Current Ratio
PLUR 0.4x
vs
Sector Avg 2.0x
PLUR Sector
Debt/Equity
PLUR 0.0x
vs
Sector Avg 0.6x
PLUR Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Pluri Inc. Stock Overvalued? PLUR Valuation Analysis 2026

Based on fundamental analysis, Pluri Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
-2,411.1%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Pluri Inc. Balance Sheet: PLUR Debt, Cash & Liquidity

Current Ratio
0.43x
Quick Ratio
0.43x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
-14.85x
Long-term Debt
$1.3M

PLUR Revenue & Earnings Growth: 5-Year Financial Trend

PLUR 5-year financial data: Year 2025: Revenue $1.3M, Net Income -$20.9M, EPS $-3.99.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Pluri Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.99 indicates the company is currently unprofitable.

PLUR Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-2,178.2%
Free cash flow / Revenue

PLUR Quarterly Earnings & Performance

Quarterly financial performance data for Pluri Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q2 2026 $185.0K -$3.0M $-0.53
Q1 2026 $316.0K -$5.9M $-0.65
Q3 2025 $71.0K -$5.3M $-0.94
Q2 2025 $105.0K -$3.0M $-0.53
Q1 2025 $54.0K -$5.0M $-0.96
Q3 2024 $71.0K -$5.3M $-1.01
Q2 2024 $2.0K -$4.9M $-0.12
Q1 2024 $54.0K -$5.0M $-0.12

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Pluri Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$10.6M
Cash generated from operations
Capital Expenditures
$563.0K
Investment in assets
Dividends
None
No dividend program

PLUR SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Pluri Inc. (CIK: 0001158780)

📋 Recent SEC Filings

Date Form Document Action
Mar 27, 2026 8-K ea0283653-8k_pluri.htm View →
Mar 2, 2026 8-K ea0279347-8k_pluri.htm View →
Feb 12, 2026 10-Q ea0275848-10q_pluri.htm View →
Jan 22, 2026 8-K ea0273651-8k_pluri.htm View →
Jan 5, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about PLUR

What is the AI rating for PLUR?

Pluri Inc. (PLUR) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are PLUR's key strengths?

Claude: Positive gross margin of 39.1% on limited product sales demonstrates product unit economics. Maintains $4.7M in cash reserves providing minimal operating runway.

What are the risks of investing in PLUR?

Claude: Negative stockholders' equity of -$14.6M represents technical balance sheet insolvency. Severe liquidity crisis with current ratio of 0.43x - unable to cover short-term obligations with current assets.

What is PLUR's revenue and growth?

Pluri Inc. reported revenue of $514.0K.

Does PLUR pay dividends?

Pluri Inc. does not currently pay dividends.

Where can I find PLUR SEC filings?

Official SEC filings for Pluri Inc. (CIK: 0001158780) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is PLUR's EPS?

Pluri Inc. has a diluted EPS of $-1.36.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is PLUR a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Pluri Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is PLUR stock overvalued or undervalued?

Valuation metrics for PLUR: ROE of N/A (sector avg: 15%), net margin of -2,411.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy PLUR stock in 2026?

Our dual AI analysis gives Pluri Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is PLUR's free cash flow?

Pluri Inc.'s operating cash flow is $-10.6M, with capital expenditures of $563.0K. FCF margin is -2,178.2%.

How does PLUR compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -2,411.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.43 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 14, 2026 | Data as of: 2025-12-31 | Powered by Claude AI